LUMOS PHARMA, INC. – Trademark Portfolio

Entity Type: 03

LUMOS PHARMA, INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include LUMOS PHARMA. The owner is based in Austin, TX.

4200 Marathon Blvd., Ste. 200

Austin, TX 78756

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

LUMOS PHARMA, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does LUMOS PHARMA, INC. have?

LUMOS PHARMA, INC. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending, 2 abandoned, 1 cancelled.

What trademark classes does LUMOS PHARMA, INC. file in?

LUMOS PHARMA, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are LUMOS PHARMA, INC.'s most well-known trademarks?

LUMOS PHARMA, INC.'s registered trademark portfolio includes well-known marks such as LUMOS PHARMA. These are among 1 currently registered trademark in the portfolio.

What is LUMOS PHARMA, INC.'s trademark registration success rate?

LUMOS PHARMA, INC. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.